{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:40:54Z","timestamp":1777948854176,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,3]]},"DOI":"10.7759\/cureus.108181","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T20:59:58Z","timestamp":1777841998000},"source":"Crossref","is-referenced-by-count":0,"title":["Cytomegalovirus (CMV) Viremia Presenting as a Heart Failure Exacerbation"],"prefix":"10.7759","author":[{"given":"Chirag","family":"Lodha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J","family":"Basile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhaas","family":"Singireddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12349","article-title":"Increased risk of breakthrough infection among cytomegalovirus donor-positive\/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis","volume":"17","author":"Stevens DR","year":"2015","unstructured":"Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J. Increased risk of breakthrough infection among cytomegalovirus donor-positive\/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transpl Infect Dis. 2015, 17:163-73. 10.1111\/tid.12349","journal-title":"Transpl Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14233","article-title":"Five-year single-center analysis of cytomegalovirus viremia in kidney transplant recipients and possible implication for novel prophylactic therapy approaches","volume":"26","author":"Trappe M","year":"2024","unstructured":"Trappe M, Affeldt P, Grundmann F, et al.. Five-year single-center analysis of cytomegalovirus viremia in kidney transplant recipients and possible implication for novel prophylactic therapy approaches. Transpl Infect Dis. 2024, 26:e14233. 10.1111\/tid.14233","journal-title":"Transpl Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11020458","article-title":"Relationship between cytomegalovirus viremia and long-term outcomes in kidney transplant recipients with different donor ages","volume":"11","author":"Diena D","year":"2023","unstructured":"Diena D, Allesina A, Fop F, et al.. Relationship between cytomegalovirus viremia and long-term outcomes in kidney transplant recipients with different donor ages. Microorganisms. 2023, 11:3. 10.3390\/microorganisms11020458","journal-title":"Microorganisms"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13781","article-title":"Easier control of late-onset cytomegalovirus disease following universal prophylaxis through an early antiviral immune response in donor-positive, recipient-negative kidney transplants","volume":"16","author":"Kaminski H","year":"2016","unstructured":"Kaminski H, Couzi L, Garrigue I, Moreau JF, D\u00e9chanet-Merville J, Merville P. Easier control of late-onset cytomegalovirus disease following universal prophylaxis through an early antiviral immune response in donor-positive, recipient-negative kidney transplants. Am J Transplant. 2016, 16:2384-94. 10.1111\/ajt.13781","journal-title":"Am J Transplant"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2017.12.025","article-title":"Prevention of late-onset cytomegalovirus infection and disease in donor-positive\/recipient-negative kidney transplant recipients using low-dose valganciclovir","volume":"50","author":"Nanmoku K","year":"2018","unstructured":"Nanmoku K, Shinzato T, Kubo T, Shimizu T, Kimura T, Yagisawa T. Prevention of late-onset cytomegalovirus infection and disease in donor-positive\/recipient-negative kidney transplant recipients using low-dose valganciclovir. Transplant Proc. 2018, 50:124-9. 10.1016\/j.transproceed.2017.12.025","journal-title":"Transplant Proc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13798","article-title":"Management of BK viremia is associated with a lower risk of subsequent cytomegalovirus infection in kidney transplant recipients","volume":"34","author":"Jorgenson MR","year":"2020","unstructured":"Jorgenson MR, Descourouez JL, Lyu B, Astor BC, Saddler CM, Mandelbrot DA, Parajuli S. Management of BK viremia is associated with a lower risk of subsequent cytomegalovirus infection in kidney transplant recipients. Clin Transplant. 2020, 34:e13798. 10.1111\/ctr.13798","journal-title":"Clin Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2024.105678","article-title":"Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: a randomized controlled trial in adult and pediatric kidney transplant recipients","volume":"172","author":"Verghese PS","year":"2024","unstructured":"Verghese PS, Evans MD, Hanson A, Hathi J, Chinnakotla S, Matas A, Balfour HH Jr. Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: a randomized controlled trial in adult and pediatric kidney transplant recipients. J Clin Virol. 2024, 172:105678. 10.1016\/j.jcv.2024.105678","journal-title":"J Clin Virol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.893232","article-title":"QuantiFERON-cytomegalovirus assay for prediction of cytomegalovirus viremia in kidney transplant recipients: study from high cytomegalovirus seroprevalence country","volume":"12","author":"Pongsakornkullachart K","year":"2022","unstructured":"Pongsakornkullachart K, Chayakulkeeree M, Vongwiwatana A, Kantakamalakul W, Skulratanasak P, Phoompoung P. QuantiFERON-cytomegalovirus assay for prediction of cytomegalovirus viremia in kidney transplant recipients: study from high cytomegalovirus seroprevalence country. Front Cell Infect Microbiol. 2022, 12:8. 10.3389\/fcimb.2022.893232","journal-title":"Front Cell Infect Microbiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1180769","article-title":"Torque teno virus viremia and QuantiFERON(\u00ae)-CMV assay in prediction of cytomegalovirus reactivation in R+ kidney transplant recipients","volume":"10","author":"Mafi S","year":"2023","unstructured":"Mafi S, Essig M, Rerolle JP, et al.. Torque teno virus viremia and QuantiFERON(\u00ae)-CMV assay in prediction of cytomegalovirus reactivation in R+ kidney transplant recipients. Front Med (Lausanne). 2023, 10:9. 10.3389\/fmed.2023.1180769","journal-title":"Front Med (Lausanne)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.09.023","article-title":"Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients","volume":"65","author":"Hasegawa J","year":"2017","unstructured":"Hasegawa J, Hatakeyama S, Wakai S, et al.. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients. Int J Infect Dis. 2017, 65:50-6. 10.1016\/j.ijid.2017.09.023","journal-title":"Int J Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2019.101226","article-title":"Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: a single-center study","volume":"56","author":"Korneffel K","year":"2019","unstructured":"Korneffel K, Mitro G, Buschor K, Rees M, Ortiz J. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: a single-center study. Transpl Immunol. 2019, 56:6. 10.1016\/j.trim.2019.101226","journal-title":"Transpl Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000005173","article-title":"Cell-mediated immunity to guide primary prophylaxis for CMV infection in organ transplant recipients: a multicenter single-arm prospective study","volume":"109","author":"Solera JT","year":"2025","unstructured":"Solera JT, Ferreira VH, Cervera C, et al.. Cell-mediated immunity to guide primary prophylaxis for CMV infection in organ transplant recipients: a multicenter single-arm prospective study. Transplantation. 2025, 109:527-35. 10.1097\/TP.0000000000005173","journal-title":"Transplantation"},{"key":"ref13","article-title":"CMV valganciclovir prophylaxis versus preemptive therapy after renal transplantation: three year results of a randomized clinical trial","volume":"94","author":"Hauser IA","year":"2010","unstructured":"Hauser IA, Wolf G, Wolters H, Nitschke M, Vonend O, Witzke O. CMV valganciclovir prophylaxis versus preemptive therapy after renal transplantation: three year results of a randomized clinical trial. Transplantation. 2010, 94:83.","journal-title":"Transplantation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002024","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical trial","volume":"102","author":"Witzke O","year":"2018","unstructured":"Witzke O, Nitschke M, Bartels M, et al.. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical trial. Transplantation. 2018, 102:876-82. 10.1097\/TP.0000000000002024","journal-title":"Transplantation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-022-01373-2","article-title":"De-novo CMV infection manifesting as interstitial nephritis in\u00a0a high-risk kidney recipient with concurrent urologic complications: lessons for the clinical nephrologist","volume":"35","author":"Gama A","year":"2022","unstructured":"Gama A, Park S, Ellis CL. De-novo CMV infection manifesting as interstitial nephritis in\u00a0a high-risk kidney recipient with concurrent urologic complications: lessons for the clinical nephrologist. J Nephrol. 2022, 35:1923-6. 10.1007\/s40620-022-01373-2","journal-title":"J Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13693","article-title":"The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients","volume":"23","author":"Jorgenson MR","year":"2021","unstructured":"Jorgenson MR, Descourouez JL, Garg N, et al.. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients. Transpl Infect Dis. 2021, 23:e13693. 10.1111\/tid.13693","journal-title":"Transpl Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2023.11.021","article-title":"Low-dose vs standard-dose valganciclovir for cytomegalovirus prophylaxis after kidney transplantation: a single-center retrospective analysis","volume":"56","author":"Farkas K","year":"2024","unstructured":"Farkas K, Varga M, Dinnyes I, et al.. Low-dose vs standard-dose valganciclovir for cytomegalovirus prophylaxis after kidney transplantation: a single-center retrospective analysis. Transplant Proc. 2024, 56:105-10. 10.1016\/j.transproceed.2023.11.021","journal-title":"Transplant Proc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.18433\/J3805B","article-title":"Effectiveness of valganciclovir 900mg versus 450mg for cytomegalovirus prophylaxis in renal transplantation: a systematic review and meta-analysis","volume":"20","author":"Xin W","year":"2017","unstructured":"Xin W, Hui Y, Xiaodong Z, Xiangli C, Shihui W, Lihong L. Effectiveness of valganciclovir 900mg versus 450mg for cytomegalovirus prophylaxis in renal transplantation: a systematic review and meta-analysis. J Pharm Pharm Sci. 2017, 20:168-83. 10.18433\/J3805B","journal-title":"J Pharm Pharm Sci"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.4103\/ijot.ijot_84_20","article-title":"Evaluation of alternate-day valganciclovir prophylaxis for cytomegalovirus disease prevention in moderate risk renal transplant patients: a retrospective observational study","volume":"15","author":"Bhuwania P","year":"2021","unstructured":"Bhuwania P, Veerappan I, Sethuraman R. Evaluation of alternate-day valganciclovir prophylaxis for cytomegalovirus disease prevention in moderate risk renal transplant patients: a retrospective observational study. Indian J Transplant. 2021, 15:104-10.","journal-title":"Indian J Transplant"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfx145","article-title":"High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation","volume":"11","author":"Rissling O","year":"2018","unstructured":"Rissling O, Naik M, Brakemeier S, et al.. High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation. Clin Kidney J. 2018, 11:564-73. 10.1093\/ckj\/sfx145","journal-title":"Clin Kidney J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/481801-cytomegalovirus-cmv-viremia-presenting-as-a-heart-failure-exacerbation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T20:59:58Z","timestamp":1777841998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/481801-cytomegalovirus-cmv-viremia-presenting-as-a-heart-failure-exacerbation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.108181","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,3]]}}}